Fig. 5: Association between PD-1+CD8+ T cell abundance and targetable genomic alterations in patients with Stage III gastric cancer. | British Journal of Cancer

Fig. 5: Association between PD-1+CD8+ T cell abundance and targetable genomic alterations in patients with Stage III gastric cancer.

From: Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer

Fig. 5

a Heatmap demonstrated the genomic alterations of potential therapeutic targets in GC based on PD-1+CD8+ T cell signature level. b Quantification analyses of therapy-associated signal pathway signature between PD-1+CD8+ T cell signature low/high-expression subgroup among Stage III GC patients in ACRG cohort: TGFB signalling pathway (P < 0.001), VEGF/VEGFR signalling network (P < 0.001), ERBB signalling pathway (P < 0.05), MUC17 relative mRNA expression (P < 0.001), HRR signalling pathway (P < 0.010); HRR, homologous recombination repair. Data were analysed by Mann–Whitney U test. Small horizontal lines indicate the mean (±SD). *P < 0.05, **P < 0.01, ***P < 0.001, ns refers to not significant. P values presented here were two-tailed.

Back to article page